254 (PB242): HMPL-500, a potent and selective EZH1/EZH2 dual inhibitor, demonstrates superior anti-tumor activity in preclinical models of hematological malignancies and solid tumorsLiang Ge, Wei Su, H. Yu et al.|European Journal of Cancer|2024Cited by 0